New cancer drug SG2918 enters first human tests
NCT ID NCT06167486
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests an experimental drug called SG2918 in 17 people with advanced cancers that no longer respond to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive the drug by IV every three weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SG2918 (an experimental drug given by IV every 3 weeks)
- What this could lead to
- If it works, this could point toward a new treatment option for people with advanced cancers that have stopped responding to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 17 people, focused on safety and dosing—not on proving the drug works. Many drugs fail at this stage, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANT TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chongqing University Cancer Hospital
Chongqing, Chongqing Municipality, 400000, China
-
Henan Cancer Hospital
Zhengzhou, Henan, 450003, China
-
Hunan Cancer Hospital
Changsha, Hunan, 410031, China
-
Shanghai first maternity and infant hospital
Shanghai, Shanghai Municipality, 200126, China
-
Shanxi Provincial Cancer Hospital
Taiyuan, Shanxi, 30013, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310005, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New pill targets cancer growth at the genetic level
- New drug duo shows promise for tough cancers
- New cancer drug LBL-033 tested in 26 patients – safety first
- Two-Antibody combo takes on advanced cancers
- New drug cocktail shows promise against tough cancers
- Engineered macrophages take on Hard-to-Treat cancers